Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptoms decrease ≥30% 81% Improvement Relative Risk Symptoms decrease ≥70% 58% Symptoms decrease ≥90% 36% Radiographic improvement 1% Viral clearance -8% c19early.org/q Shah et al. NCT04723524 Quercetin RCT EARLY TREATMENT Is early treatment with quercetin beneficial for COVID-19? Double-blind RCT 300 patients in Pakistan (September 2020 - August 2021) Greater improvement with quercetin (p<0.000001) Shah et al., medRxiv, doi:10.1101/2022.05.16.22275074 Favors quercetin Favors control
Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial
Shah et al., medRxiv, doi:10.1101/2022.05.16.22275074 (Preprint), NCT04723524 (history)
Shah et al., Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized.., medRxiv, doi:10.1101/2022.05.16.22275074 (Preprint), NCT04723524
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 300 outpatients in China, showing improved recovery with Jinhua Qinggan treatment, but no significant difference in viral clearance or radiographic findings. Jinhua Qinggan includes quercetin, rutin, luteolin, wogonin, myricetin, ursolic acid, chrysoeriol, glabridin, stigmasterol, and kaempferol. This study is excluded in meta analysis: combination of several ingredients with unclear dosage.
risk of no symptoms decrease ≥30%, 80.6% lower, RR 0.19, p < 0.001, treatment 26 of 150 (17.3%), control 134 of 150 (89.3%), NNT 1.4.
risk of no symptoms decrease ≥70%, 58.1% lower, RR 0.42, p < 0.001, treatment 62 of 150 (41.3%), control 148 of 150 (98.7%), NNT 1.7.
risk of no symptoms decrease ≥90%, 35.8% lower, RR 0.64, p < 0.001, treatment 95 of 150 (63.3%), control 148 of 150 (98.7%), NNT 2.8.
risk of no radiographic improvement, 0.7% lower, RR 0.99, p = 1.00, treatment 112 of 128 (87.5%), control 111 of 126 (88.1%), NNT 168.
risk of no viral clearance, 8.1% higher, RR 1.08, p = 0.48, treatment 93 of 150 (62.0%), control 86 of 150 (57.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shah et al., 20 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Pakistan, preprint, 10 authors, study period 22 September, 2020 - 23 August, 2021, trial NCT04723524 (history).
Contact: raza.shah@iccs.edu, liuqingquan@bjzhongyi.com, dennislam@hkcmer.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperQuercetinAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.05.16.22275074; this version posted May 20, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial Muhammad Raza Shah*1, Samreen Fatima1, Sehrosh Naz Khan1, Shafiullah1, Gulshan Himani2, Kelvin Wan3, Timothy Lin3, Johnson Y.N. Lau4, Qingquan Liu*5, Dennis S.C. Lam*3,4 1] Center for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, 2] The Indus Hospital Karachi, Plot C-76, Sector 31/5, Opposite Korangi Crossing, Darussalam Society Sector 39, Karachi, Sindh, Pakistan 3] Hong Kong Alliance of Integrated Medicine Against Covid, Hong Kong 4] School of Chinese Medicine of Hong Kong, Baptist University, Hong Kong 5] Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, People’s Republic of China *E-mail address for correspondence Muhammad Raza Shah: raza.shah@iccs.edu , Qingquan Liu: liuqingquan@bjzhongyi.com, Dennis S.C. Lam: dennislam@hkcmer.com NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.05.16.22275074; this version posted May 20, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract Background: Key findings from the World Health Organization Expert Meeting on Evaluation of Traditional Chinese Medicine in treating COVID-19 reported that TCMs are beneficial, particularly for mild-to-moderate cases. The efficacy of Jinhua Qinggan Granules (JHQG) in COVID-19 patients with mild symptoms has yet to be clearly defined. Methods: We conducted a phase 2/3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of treatment with JHQG in mild, nonhospitalized, laboratoryconfirmed COVID-19 patients. Participants were randomly assigned to receive 5g/sacket of JHQG or placebo granules orally thrice daily for 10 days. The primary outcomes were the improvement in clinical symptoms and proportion tested negative on viral PCR after treatment. Secondary outcomes were the time to recovery from clinical symptoms and changes in white blood cells (WBC) and acute phase reactants (C-reactive protein (CRP) and ferritin) 10-15 days after treatment. Results: A total of 300 patients were randomly assigned to receive JHQG (150 patients) and placebo (150 patients). Baseline characteristics were similar in the two groups. In the modified intention-to-treat analysis, JHQG showed greater clinical efficacy (82.67%) after 10 days of treatment compared with the placebo group (10.74%) (rate difference: 71.93%; 95% CI 64.09 79.76). The proportion of patients with a negative PCR after treatment were comparable (rate difference: -4.67%; 95% CI -15.76 - 6.42). While all changes in WBC, ferritin, and CRP levels showed a statistically significant decline..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit